Valsartan 80 mg Tablet
Valsartan
Prescription medication
Hallym Pharmaceutical Co., Ltd.
MFDS item code 201105416 · Notified 2011.08.18
This product's status changed to Approval withdrawn on 2023.07.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to reduce the risk of death in patients with essential hypertension, heart failure intolerant to ACE inhibitors, and left ventricular dysfunction after myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time every day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended oral dose is 80 mg of valsartan once daily. The blood-pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If further blood-pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily. Over the following several weeks, the dose may be increased, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension: The safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication may cause serious harm to the fetus when taken during pregnancy, particularly in the second and third trimesters, so if pregnancy is confirmed, treatment must be discontinued immediately. It should not be used in patients with an allergy to this drug, severe liver or kidney disease, or a history of specific angioedema. Elderly patients, patients with hyperkalemia, those with impaired hepatic function, and those with heart or vascular issues should be monitored more carefully during administration, as hypotension or changes in renal function may occur. Dizziness or symptoms of hypotension may occur while taking this medication; therefore, caution is needed when driving or operating machinery. Patients who are likely to have elevated potassium levels or are taking potassium-sparing diuretics should have their serum potassium levels monitored closely. When used in combination with other antihypertensives or non-steroidal anti-inflammatory drugs, the drug's efficacy may be reduced or renal function may be affected, so consultation with healthcare professionals is advised. This medication is not recommended for breastfeeding women, and if it must be taken, cessation of breastfeeding is advised. The safety and efficacy in pediatric and adolescent patients have not yet been established, so use in this age group is discouraged. In case of overdose, severe hypotension or altered consciousness may occur, requiring immediate medical attention for appropriate treatment. Keep out of reach of children and do not transfer to other containers to maintain the drug's quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture; therefore, it should be stored in a sealed container. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its efficacy.
Light red round film-coated tablet
98 tablets (14 tablets/PTP packaging x 7), 30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan
Prescription medication
Hallym Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.